DESCRIPTION:

Hyperhidrosis is defined as excessive sweating, beyond a level required to maintain normal body temperature, in response to heat exposure or exercise. It can be classified as primary or secondary.

Primary focal hyperhidrosis is idiopathic, typically involving the hands (palmar), feet (plantar), head or face (craniofacial), or axillae (underarms).

Secondary gustatory hyperhidrosis is excessive sweating on ingesting highly spiced foods. This trigeminovascular reflex typically occurs symmetrically on the scalp or face and predominately over the forehead, lips, and nose. Secondary facial gustatory occurs independently of the nature of the ingested food. This phenomenon frequently occurs after injury or surgery in the region of the parotid gland.

POSITION STATEMENT:

NOTE: For treatment of hyperhidrosis using botulinum toxin injections, please refer to MCG 09-J0000-29 Botulinum Toxin.

Primary focal hyperhidrosis

Treatment of primary focal hyperhidrosis meets the definition of medical necessity for any of the following conditions:

- Acrocyanosis of the hands
- History of recurrent skin maceration with bacterial or fungal infections
- History of recurrent secondary infections
• History of persistent eczematous dermatitis despite medical treatments with topical dermatologic or systemic pharmacotherapy

The following treatments **meet the definition of medical necessity** for treatment of primary **focal** hyperhidrosis:

• Topical agents
• Systemic pharmacotherapy
• Surgical excision of axillary sweat glands, if conservative treatment with topical or systemic pharmacotherapy has failed
• Endoscopic transthoracic sympathectomy (ETS), if conservative treatment with topical or systemic pharmacotherapy has failed
• Iontophoresis

**Severe secondary gustatory hyperhidrosis**

The following treatments for severe secondary gustatory hyperhidrosis **meet the definition of medical necessity**:

• Topical agents
• Surgical options (e.g. tympanic neurectomy) if conservative treatment has failed

The following treatments for hyperhidrosis are considered **experimental or investigational**:

• Axillary liposuction
• Microwave treatment
• Radiofrequency ablation
• Lumbar sympathectomy

There is insufficient clinical evidence in the peer-reviewed literature to support conclusions regarding long-term safety, efficacy or improvement in net health outcomes.

**BILLING/CODING INFORMATION:**

The following codes may be used to describe treatments for hyperhidrosis. There is no specific code describing surgical excision of the axillary sweat glands for hyperhidrosis.

**CPT Coding:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>32664</td>
<td>Thoracotomy; with thoracic sympathectomy</td>
</tr>
<tr>
<td>69676</td>
<td>Tympanic neurectomy</td>
</tr>
<tr>
<td>97033</td>
<td>Iontophoresis, each 15 minutes</td>
</tr>
</tbody>
</table>

**REIMBURSEMENT INFORMATION:**

Refer to sections entitled **POSITION STATEMENT**.
**PROGRAM EXCEPTIONS:**

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) was found at the time of the last guideline review date.

**DEFINITIONS:**

Aluminum chloride: a common component of over-the-counter antiperspirants, although a prescription product is available (Drysol). Although the mechanism is unclear, aluminum chloride is associated with atrophy of the secretory cells seen in eccrine sweat glands. Aluminum chloride is predominantly used to treat axillary hyperhidrosis and not palmar or volar hyperhidrosis.

Eccrine glands: any of the rather small sweat glands that produce a fluid secretion without removing cytoplasm from the secreting cells and that are restricted to the human skin (eccrine sweat gland).

Functional impairment: difficulties that substantially interfere with or limit role functioning in one or more major life activities (eg, may interfere with the ability to maintain appropriate hygiene, or may interfere with work in certain professions).

Gustatory: of or relating to the sense of taste. Gustatory hyperhidrosis conditions include Frey’s syndrome, encephalitis, syringomyelia, diabetic neuropathies, herpes zoster parotitis and parotid abscess.

Iontophoresis: a technique that involves the use of an electric current to introduce various ions through the skin.

Volar: relating to the palm of the hand or the sole of the foot; located on the same side as the palm of the hand.

**RELATED GUIDELINES:**

*Botulinum Toxins, 09-J0000-29*

**OTHER:**

Index terms:

- Endoscopic sympathectomy
- Gustatory hyperhidrosis
- Hyperhidrosis
- Iontophoresis
- Sweating, excessive
- Sympathectomy, thoracic
- Thoracoscopic sympathectomy
REFERENCES:
10. Hayes Medical Technology Directory: Endoscopic Sympathectomy Treatment for Hyperhidrosis 01/14/03; updated 02/15/08.


29. Stoleman, LP, MD, FACP< FRCP (C). Hyperhidrosis Medical and Surgical Treatment. Eplasty. 2008; 8: e22. Published online 2008 April 18.


**COMMITTEE APPROVAL:**
This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy & Coverage Committee on 12/02/21.

**GUIDELINE UPDATE INFORMATION:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/15/03</td>
<td>New Medical Coverage Guideline.</td>
</tr>
<tr>
<td>05/15/04</td>
<td>Scheduled review; added coverage statement for surgical excision of sweat glands for axillary hyperhidrosis; added investigational statement for axillary liposuction.</td>
</tr>
<tr>
<td>04/15/06</td>
<td>Scheduled review; no change in coverage statement; added cross-reference statement regarding Botox injections for treating hyperhidrosis; removed aluminum chloride from the list of treatments discussed in this MCG; added “refractory to standard medical treatment” to the coverage statement in When Services Are Covered.</td>
</tr>
<tr>
<td>04/15/07</td>
<td>Scheduled review; no change in coverage statement.</td>
</tr>
<tr>
<td>06/15/07</td>
<td>Reformatted guideline.</td>
</tr>
<tr>
<td>04/15/08</td>
<td>Scheduled review; no change in position statement. Updated references.</td>
</tr>
<tr>
<td>04/15/09</td>
<td>Scheduled review. Update references and position statement with addition of indication for the use of Botox.</td>
</tr>
<tr>
<td>04/15/10</td>
<td>Annual review; investigational position statement for chemical or surgical lumbar sympathectomy added to guideline. References updated.</td>
</tr>
<tr>
<td>10/15/10</td>
<td>Revision; related ICD-10 codes added.</td>
</tr>
<tr>
<td>04/15/12</td>
<td>Scheduled review. Position statement maintained. Revised description section, ICD10 coding and definitions. Updated references.</td>
</tr>
<tr>
<td>04/15/13</td>
<td>Scheduled review. Revised description and position statement (designated microwave treatment for hyperhidrosis as experimental or investigational). Revised ICD9 coding, definitions and index terms. Updated references and reformatted guideline.</td>
</tr>
<tr>
<td>02/15/14</td>
<td>Revision; Program Exceptions section updated.</td>
</tr>
<tr>
<td>11/01/15</td>
<td>Revision: ICD-9 Codes deleted.</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Revision: Billing/Coding Information section updated.</td>
</tr>
<tr>
<td>10/15/18</td>
<td>Scheduled review. Revised description and position statement. Updated programs exceptions and references.</td>
</tr>
<tr>
<td>09/15/20</td>
<td>Scheduled review. Revised description, position statement, and CPT coding. Updated references.</td>
</tr>
<tr>
<td>12/15/21</td>
<td>Scheduled review. Revised description, maintained position statement and updated references.</td>
</tr>
</tbody>
</table>